Startup
Programs: Brandon BioCatalyst (CUREator)
Every investor coverage indicates participated in a round Proxima Bio raised.
| Investor | Rounds | Invested |
|---|---|---|
| Brandon BioCatalyst | Accelerator | - |
Investors whose own portfolio pages list Proxima Bio, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Tenmile | its portfolio page ↗ |
| Tin Alley Ventures | its portfolio page ↗ |
Companies Proxima Bio acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Proxima Bio. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of Australian biotech startup Proxima Bio, covering its founding, an early MRFF grant through the CUREator program, Brandon Capital's guidance, and a later larger investment that grew the team.
A profile of six life-science ventures that graduated from Melbourne bioincubator Jumar's debut program, one of which, Tessara Therapeutics, won a $3 million research grant in December.
Biotech incubator CUREator's second round distributes $12 million among 19 health-focused startups, supported by government funding, while a new MedTech program backed by $50 million arrives later in the year.
CUREator, the national biotech incubator operated by Brandon BioCatalyst, selects 19 projects for its second funding round worth $12 million, and a $50 million MRFF award will add a MedTech stream.